Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy gets go ahead to market heart drug
The drug has been cleared in 10mg, 20mg, 40mg and 80mg strengths, with 180-day market exclusivity in the US healthcare system for the 80mg strength. The FDA has
The drug has been cleared in 10mg, 20mg, 40mg and 80mg strengths, with 180-day market exclusivity in the US healthcare system for the 80mg strength. The FDA has
Despite advances in the treatment of acute coronary syndromes, the risk of recurrent cardiovascular events remains substantial. The effectiveness and safety of the drug had not previously been
The study results indicate bioequivalent pharmacokinetics between ANX-514 and the FDA-approved version of Taxotere. Furthermore, ANX-514, administered intravenously, did not cause hypersensitivity reactions in this study, as opposed
ALKS 27 is an inhaled formulation of trospium chloride based on Alkermes' AIR pulmonary technology. The study will assess the safety, tolerability, pharmacokinetics and efficacy of single doses
The receipt of FDA clearance triggers a milestone payment to the previous Montigen shareholders of $10 million, to be paid in SuperGen common stock. The phase I accelerated
The trial will investigate the efficacy and safety of three oral doses of VSF-173 for the treatment of induced excessive sleepiness in approximately 60 healthy male and female
The results are based on achievement of the primary efficacy endpoint of the trial, Summary of Pain Intensity Difference (SPID), compared to placebo. The results demonstrated that patients
XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated. The co-primary endpoints for the clinical trial
Under the terms of the agreement, Novartis is granted world-wide exclusive rights for the vaccine CYT002-NicQb and is responsible for late stage clinical development, manufacturing, and commercialization of
The lowest dose of cannabinor, a CB2 agonist, produced a statistically significant decrease in pain versus placebo, as measured by the primary endpoint. However, this drug effect was